Cessation of chemotherapy in the last few weeks of life could be an important quality-of-care benchmark. Proportion of metastatic breast cancer patients who receive end-of-life chemotherapy is not well described. We aimed to determine the prevalence and determinants of end-of-life chemotherapy use in patients with metastatic breast cancer. A retrospective cohort study using a prospectively collated database of patients with metastatic breast cancer who died between January 1, 2010, and September 30, 2014, was conducted. End-of-life chemotherapy (EOLC) use was defined as receipt of chemotherapy within 2 weeks of death (EOLC2) and receipt of chemotherapy within 4 weeks of death (EOLC4). Patients who did not receive any chemotherapy in the last 4 weeks before death were categorized as non-EOLC. We identified 274 patients with metastatic breast cancer, of whom 28 received EOLC2 (10.2%) and 62 received EOLC4 (22.6%). In comparison with non-EOLC, patients receiving EOLC4 were younger and had greater disease burden. Patients in EOLC4 group received more number of lines of chemotherapy. In a multivariable analysis, younger age at metastatic disease and greater number of metastatic organ systems involved were predictors of end-of-life chemotherapy use. Prevalence of the use of end-of-life chemotherapy in our cohort was higher than previously described. More end-of-life chemotherapy was used in younger women, and those with greater disease burden. Earlier initiation of end-of-life discussions may be targeted to such patients. 17 In the Swedish study comprising of patients who received palliative chemotherapy, the prevalence of chemotherapy use within 30 days of death among breast cancer patients was 10.9% (n = 46).
of a patient is an important determinant; 4 patients with poor functional status rarely benefit from chemotherapy, and it may even hasten death. 5 Second, physicians' perceptions of prognosis may influence end-of-life chemotherapy use. Several studies have shown that oncologists generally tend to overestimate survival in endstage cancer patients. 6, 7 Third, the patient may prefer to continue with active chemotherapeutic management rather than a symptombased palliative approach, due to societal pressures or their own perception of disease status. [8] [9] [10] Given that these factors are often multifaceted, patients continue to receive chemotherapy near the end of life, sometimes inappropriately.
A retrospective study from Australia found that 18% of 398 patients with nonhematological malignancies who were treated with palliative chemotherapy continued to receive it within 30 days of death, 8% within 14 days. 11 A Swedish hospital-based study of 374 patients with cancer who died in 2008 after having received palliative chemotherapy during the course of metastatic disease identified that 23% of them received chemotherapy within 30 days of death. 12 The American Surveillance, Epidemiology, and 
| Outcome variables
We defined end-of-life chemotherapy (EOLC) use based on the date of receipt of last chemotherapy. EOLC2 was defined as receipt of chemotherapy within 2 weeks of death, and EOLC4 was defined as receipt of chemotherapy within 4 weeks of death. Patients who did not receive any chemotherapy in the last 4 weeks before death were categorized as non-EOLC.
| Statistical analysis
Means with standard deviations and medians with ranges were used to summarize continuous variables. Categorical variables were summarized as percent of total. We used chi-square test, Fisher's exact test, and Wilcoxon rank sum test, as appropriate, to test for significant associations between patients' baseline characteristics and the receipt of chemotherapy across the three groups; data for the comparisons between EOLC4 and non-EOLC will be described in this article. To address the issue of multiple comparisons, a
Bonferroni correction is used, with P < .025 considered statistically significant in the final analysis. Predictors for EOLC4 use vs non-EOLC were determined using logistic regression models. All
statistical analyses were performed using SAS 9.4 (SAS Institute, Cary, NC, USA.)
| RESULTS
We identified 274 patients who died with metastatic breast cancer ( Median overall survival from the time of metastatic diagnosis was shorter for patients in the EOLC4 group compared to the non-EOLC group, although this was not statistically significant ( 
| DISCUSSION
Our study provides important data on the frequency of chemotherapy use within 2 and 4 weeks of death in patients with metastatic breast cancer, which was 10.2% and 22.6%, respectively. Our estimate of the prevalence of end-of-life chemotherapy use appears to be greater compared to the previous data. 12, [15] [16] [17] Such data are extremely challenging to obtain, and comparison is difficult given regional and institutional variability in use of end-of-life chemotherapy, different types of data source, changes in chemotherapy management over the years and the methodological differences between the various published studies. However, there could be several reasons why end-of-life chemotherapy use is higher in our study. First, our data are more recent compared to the prior studies Therefore, it is likely that our data on the prevalence of end-of-life chemotherapy use in metastatic breast cancer patients may be closer to the actual rates. Third, as compared to the Scandinavian countries, palliative chemotherapy administration may be more prevalent in the United States. For instance, the studies from Finland and Norway reports a prevalence of palliative chemotherapy of 37% and 52%, respectively, compared to 88% in our study. 16, 17 Fourth, patterns of practice as determined by the oncologists in an institution or group may also dictate the use of end-of-life chemotherapy and could cause variation in frequency of end-of-life chemotherapy use.
T A B L E 1 Baseline characteristics
In addition to providing data on prevalence, we also investigated the determinants of end-of-life chemotherapy use in breast cancer.
Patients who were younger and had greater burden of disease were more likely to receive end-of-life chemotherapy. The EOLC4 group had a shorter survival after diagnosis of metastatic disease compared to non-EOLC4 suggesting a more aggressive disease course in those who received end-of-life chemotherapy. Patients with CNS disease and those who had de novo metastatic disease were more likely not to receive end-of-life chemotherapy, although these associations did not reach statistical significance.
Studies have consistently shown that patients who receive endof-life chemotherapy are younger. 11, 20, 21 Older patients are more
likely to value quality of life over life prolonging measures as compared to younger patients. 22 The fact that patients with greater disease burden received more end-of-life chemotherapy could reflect the aggressiveness of the disease or may also be due to the fact that physicians are not very good at predicting survival. 7 The emphasis on using functional status as a surrogate for longevity may contribute to this factor. Although good functional status is used as a surrogate for chemotherapy benefit, there are limitations to such an assumption. A prospective cohort study of 158 patients with advanced-stage cancer identified a detrimental effect of chemotherapy on quality of life near death in those with good performance status at baseline. 5 Discussions between physicians and patients regarding end-oflife care were found to take place a median of 33 days prior to death. 23 Those patients who had end-of-life discussions earlier were less likely to receive aggressive measures before death. 
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Our study has a few limitations. We did not prospectively collect information on quality of life or functional status as it could not be accurately captured from the medical records. Additionally, the smaller sample size in our study could preclude a more detailed subset analysis. Another limitation might be related to the external validity of our study, as ours was a single institution study. Oncology practices and resource utilization might substantially differ by both institution and country.
| CONCLUSION S
Appropriately timed cessation of chemotherapy is critical in providing optimal care in patients with end-stage cancer. There is a growing concern that chemotherapy administration during the last month of life might not be effective, both in terms of prolonging survival and alleviation of symptoms.
In summary, our study describes the epidemiology of end-of-life chemotherapy use in metastatic breast cancer at a major teaching hospital in the United States. An informed patient along with timely discussion about goals of care, preferably early on in the disease course, can lead to decreased utilization of chemotherapy toward the end of life, and better quality of life. 
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